PerkinElmer, Inc. (PKI)
(Delayed Data from NYSE)
$96.59 USD
+1.71 (1.80%)
Updated May 3, 2019 04:03 PM ET
After-Market: $96.59 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$96.59 USD
+1.71 (1.80%)
Updated May 3, 2019 04:03 PM ET
After-Market: $96.59 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Why Is PerkinElmer (PKI) Down 7% Since Last Earnings Report?
by Zacks Equity Research
PerkinElmer (PKI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.
PerkinElmer (PKI) Boosts Genomic Testing Portfolio With urWGS
by Zacks Equity Research
PerkinElmer's (PKI) urWGS will improve outcomes for critically ill patients in NICUs and PICUs.
PerkinElmer (PKI) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
PerkinElmer's (PKI) first-quarter results benefit from a solid performance at Discover & Analytics Solutions business.
PerkinElmer (PKI) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
PerkinElmer (PKI) delivered earnings and revenue surprises of 15.87% and 6.70%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate PerkinElmer (PKI) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
PerkinElmer (PKI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PerkinElmer (PKI) to Post Q1 Earnings: What's in the Cards?
by Zacks Equity Research
PerkinElmer's (PKI) first-quarter results are likely to reflect strong performance at the Diagnostics segment.
Here's Why You Should Retain PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.
PerkinElmer (PKI) Boosts In Vivo Imaging Profile With New System
by Zacks Equity Research
PerkinElmer's (PKI) launch of the Vega imaging system is likely to help the company expand its in vivo imaging portfolio.
PerkinElmer's (PKI) New Assay Kits to Detect CHO HCP Impurities
by Zacks Equity Research
PerkinElmer (PKI) launches ready-to-use HTRF and AlphaLISA no-wash assay kits to quickly identify and quantify CHO HCP impurities.
PerkinElmer's (PKI) Latest Launch to Boost Food Analysis Suite
by Zacks Equity Research
PerkinElmer's (PKI) latest launch is likely to simplify the process of critical food analyses.
Here's Why You Should Hold on to PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.
Why Is PerkinElmer (PKI) Down 4.2% Since Last Earnings Report?
by Zacks Equity Research
PerkinElmer (PKI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PerkinElmer (PKI) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
PerkinElmer's (PKI) fourth-quarter results benefit from solid performance at Discover & Analytics Solutions business.
PerkinElmer (PKI) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
PerkinElmer (PKI) delivered earnings and revenue surprises of 19.07% and 9.46%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Why PerkinElmer (PKI) Might Surprise This Earnings Season
by Zacks Equity Research
PerkinElmer (PKI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
PerkinElmer (PKI) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
PerkinElmer (PKI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PerkinElmer (PKI) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
PerkinElmer's (PKI) fourth-quarter results are likely to reflect strong performance at the Diagnostics segment.
How Investors Can Grab Better Returns for Computer and Technology Using the Zacks ESP Screener
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Here's Why You Should Hold on to PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.
Why the Earnings Surprise Streak Could Continue for PerkinElmer (PKI)
by Zacks Equity Research
PerkinElmer (PKI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
3 Promising Gene Sequencing Stocks to Watch Out For in 2022
by Trina Mukherjee
Here we look at three stocks, PKI, TMO and TXG, with robust genome sequencing capabilities that investors can keep a watch on.
Here's Why You Should Hold on to PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.
Strength Seen in PerkinElmer (PKI): Can Its 4.6% Jump Turn into More Strength?
by Zacks Equity Research
PerkinElmer (PKI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
PerkinElmer's (PKI) Latest Kit to Boost COVID-19 Surveillance
by Zacks Equity Research
PerkinElmer's (PKI) newest addition to its SARS-CoV-2 testing portfolio is expected to aid in combating the pandemic by boosting surveillance.